Company news

ALK-abello A/S news in 2026

ALK-abello A/S's news releases, calls and decks from 2026, newest first.

View company

ALK upgrades its full-year outlook

May 4, 2026

Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026

April 28, 2026

Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

March 16, 2026

New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors

March 4, 2026

Annual General Meeting in ALK-Abelló A/S on 16 March 2026

February 20, 2026

Henriette Mersebach to step down as ALK’s head of R&D

February 20, 2026

Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026

February 13, 2026

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg

February 2, 2026

ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children

January 29, 2026

ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco

January 8, 2026

Calls in 2026

Decks in 2026